US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS).

Firdapse is amifampridine phosphate or 3,4-diaminopyridine phosphate (3,4-DAP) that has obtained an orphan drug designation in the US and orphan medicinal product designation in the European Union to treat LEMS.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

LEMS is an autoimmune neuromuscular disease resulting in a decrease of the release of acetylcholine at the neuromuscular junction, triggering muscle weakness.

Firdapse acts by increasing acetylcholine release, thereby addressing muscle weakness caused by the disease.

The second Phase III, double-blind, placebo-controlled withdrawal LMS-003 trial will be conducted across clinical trial sites in the US.

See Also:

"The initiation of our second Phase III study of Firdapse in LEMS patients is a significant step forward on our path towards gaining approval for Firdapse."

The trial will test the safety and efficacy of Firdapse while treating approximately 28 subjects with LEMS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will share the same co-primary endpoints with the first Phase III trial, which tested Firdapse for the treatment of LEMS.

Catalyst CEO Patrick McEnany said: "The initiation of our second Phase III study of Firdapse in LEMS patients is a significant step forward on our path towards gaining approval for Firdapse.

"We believe we have a clearly defined development and regulatory pathway for Firdapse in the treatment of LEMS and remain focused on our goal of improving access to treatments for patients with this significant unmet need."

Additionally, the US Food and Drug Administration (FDA) has approved Catalyst to include patients from its expanded access programme as study subjects in this second trial.

The company is planning to re-submit a new drug application (NDA) for its product and is expecting the train results in the second half of next year.